Kyle Munz

The World Health Organization has declared the second mpox global emergency in 2 years. Here are 5 things to know about mpox and the current outbreak.

A retrospective, single-center cohort study utilized liver ultrasound, serum collection, and proteome analysis to draw associations between spinal motor neuron (SMN) protein depletion and heightened risk for fatty liver disease in spinal muscular atrophy (SMA).

The majority of federal savings indicated by the Inflation Reduction Act's Drug Price Negotiation Program can be attributed to 3 drugs.

Changes in formulary coverage for 2024 are impacting Medicare patients' access to and ability to afford various prescription medications.

Maria Amaya, MD, PhD, University of Colorado School of Medicine, explores discrepancies between real-world data and clinical trial outcomes, as well as her experience ensuring the reliability of real-world analysis.

Andrew Hantel, MD, Dana-Farber Cancer Institute, discusses factors contributing to disparities in oncology clinical trial enrollment.

Caitlin Kindberg, a patient advocate from Nashville, Tennessee, discusses her experience finding proper treatment for idiopathic hypersomnia and the challenges associated with living with this condition.

The persistence of per- and polyfluoroalkyl substances (PFAS), otherwise known as "forever chemicals," poses a great threat to the environment and public health, as demonstrated by continually emerging research.

Christopher Depner, PhD, assistant professor of health and kinesiology, University of Utah, speaks to the current reliability of wearable sleep devices to impact health outcomes, privacy concerns, and more.

New survey data reveals that more than 25% of those aged 50 years and older assume caregiver responsibilities.

Minnesota Gov. Tim Walz has been named as Vice President Kamala Harris' Democratic running mate for the 2024 presidential election and has a proven track record in health care reform.

The extension of the TOPAZ study provided support for the long-term benefits and safety of apitegromab therapy in patients with spinal muscular atrophy (SMA) at 36 months.

A systematic analysis that reviewed screening for sickle cell retinopathy in patients with sickle cell disease (SCD) underscores the importance of advanced imaging measures and further research on screening implementation methods.

Results from a single-center, observational, prospective study suggested that inflammatory markers could predict disease severity and treatment efficacy for patients with spinal muscular atrophy (SMA).

The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.

The phase 3 PEGASUS trial found that patients with paroxysmal nocturnal hemoglobinuria (PNH) may still experience anemia following recommended therapies, underscoring the need for further research.

Mark Bleackley, PhD, chief scientific officer of Incannex, discusses in further detail the need for a pharmacotherapy like IHL-42X in obstructive sleep apnea (OSA) and the medication's underlying mechanisms.

A cross-sectional study found that static pain measures could be useful for predicting fatigue severity in patients with sickle cell disease (SCD).

A new report provided updated figures estimated the birth prevalence of spinal muscular atrophy (SMA) in the US.

Part of the Institute for Value-Based Medicine series, the June 20, 2024, event was presented with Banner MD Anderson in Phoenix, Arizona.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, details results from the ALKS 2680 trial and the study's next steps.

A retrospective database analysis demonstrated the high clinical burden experienced by patients with severe deficiencies of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP)–related diagnoses.

A multicenter pilot study concluded that dual therapy in spinal muscular atrophy (SMA) does not provide further benefits to infants at risk for SMA type 1.

An investigation into the burden of dilated perivascular spaces (dPVS) in children with sickle cell disease (SCD) confirmed that those with SCD experience more severe manifestations of dPVS compared with the general population.

Mark Bleackley, PhD, chief scientific officer, Incannex, details the progress of the ongoing RePOSA trial, which is assessing the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA).

Michael A. Choti, MD, MBA, Banner MD Anderson, cochaired the second annual Advancing Value-Based Oncology Care meeting and shared insights into the goals of this year's event and value-based medicine as a whole.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses the hopeful future of treatment in idiopathic hypersomnia.

Sindhuja Kadambi, MD, MS, University of Rochester Medical Center, discussed in detail the unique considerations necessary for oncology care in the aging population.

Matthew Callister, MD, Banner Health, discusses the advantage of value-based oncology care as a platform for collaboration.